Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept vs Ranibizumab Injection Frequency in CRVO
NCT02274259Phase 4Completed
- Start
- Oct 2014
- Primary completion
- Jun 2015
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aflibercept in central retinal vein occlusion (CRVO) (2 arms). Primary endpoint: Number of needed injections at 18 months. Started Oct 2014; status: completed.
02
Drugs
aflibercept
03
Conditions
central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on NCT02274259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02274259.